Missing Information
  • A System Error Has Occured:0177 - Failed to Load All Sections.
Form Type:  4
Filing Date:  10/18/2021 
CIK:  0000875320 
City, State, Zip:  BOSTON, Massachusetts 02210 
Telephone:  (617) 341-6393 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
5.87 (2.44%)  
Trade Time: 
May 13  
Market Cap: 
Trade VRTX now with 

© 2022  
Description of Business
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. We have multiple approved medicines that treat the underlying cause of cystic fibrosis, or CF, a life-threatening genetic disease, and we have several ongoing clinical and research programs to advance and extend treatment of CF. Beyond CF, we have a pipeline of investigational therapies in other serious diseases where we are leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Marketed Products Our goal in CF is to develop treatment regimens that will provide benefits to all people with CF and will enhance the benefits currently provided to people taking our medicines.